Associations between betel nut (Areca catechu) and symptoms of schizophrenia among patients in Nepal: A longitudinal study

Psychiatry Research

Volumn 169, Issue 3, 2009, Pages 203-211

  Bales, Alicia ^a   Peterson, Michael J ^a   Ojha, Saroj ^b   Upadhaya, Kapil ^c   Adhikari, Baikunta ^d   Barrett, Bruce ^e  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b TRIBHUVAN UNIVERSITY   (Nepal)

^c Patan Mental Hospital   (Nepal)

^d Department of Family Medicine ^*  (Nepal)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Arecoline; Cholinergic; Nepal; Partial muscarinic agonist; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BETEL NUT; CONTROLLED STUDY; FEMALE; FOOD INTAKE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEPAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL INTERACTION;

ADULT; ARECA; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; EMPLOYMENT; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEPAL; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; STATISTICS AS TOPIC; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 70349392709     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.06.006     Document Type: Article

References (38)

1. Bosc M., Dubini A., and Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-Evaluation Scale. European Neuropsychopharmacology 7 Supp.1 (1997) S57-S70
2. Burton-Bradley B.G. Arecaidinism: betel chewing in transcultural perspective. Canadian Journal of Psychiatry 24 (1979) 481-488
3. Bymaster F.P., Shannon H.E., Rasmussen K., DeLapp N.W., Ward J.S., Calligaro D.O., Mitch C.H., Whitesitt C., Ludvigsen T.S., Sheardown M., Swedberg M., Rasmusse T., Olsen P.H., Jeppesen L., Sauerberg P., and Fink-Jensen A. Potential role of muscarinic receptors in schizophrenia. Life Sciences 64 6-7 (1999) 527-534
4. Casey D.E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99 Supp. (1989) S47-S53
5. Cawte J. Psychoactive substances of the South Seas: betel, kava and pituri. The Australian and New Zealand Journal of Psychiatry 19 (1985) 83-87
6. Christie J.E., Shering A., Ferguson J., and Glen A.I. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. British Journal of Psychiatry 138 (1981) 46-50
7. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biological Psychiatry 48 5 (2000) 381-388
8. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8,9,10, and 46 and the effects of neuroleptic drug treatment. American Journal of Psychiatry 158 6 (2001) 918-925
9. Davis K.L., Berger P.A., Hollister L.E., and Barchas J.D. Cholinergic involvement in mental disorders. Life Sciences 22 (1978) 1865-1872
10. Duke J.A. Promising phytomedicinals. Journal of Naturopathic Medicine 2 (1991) 48-52
11. Ellis J.R., Ellis K.A., Bartholomeus C.F., Harrison B.J., Wesnes K.A., Erskine F.F., Vitetta L., and Nathan P.J. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. International Journal of Neuropsychopharmacology 9 2 (2006) 175-189
12. Felder C.C., Bymaster F.P., Ward J., and DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. Journal of Medicinal Chemistry 43 23 (2000) 4333-4353
13. Freedman R., Adler L.E., Bickford P., Byerley W., Coon H., Cullum C.M., Grifith J.M., Harris J.G., Leonard S., and Miller C. Schizophrenia and nicotinic receptors. Harvard Review of Psychiatry 2 4 (1994) 179-192
14. Friedhoff A.J., and Alpert M. A dopaminergic-cholinergic mechanism in production of psychotic symptoms. Biological Psychiatry 6 (1973) 165-169
15. Gronier B., Perry K.W., and Rasmussen K. Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area. Psychopharmacology 147 4 (2000) 347-355
16. Kay S.R., Opler L.A., and Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardization. British Journal of Psychiatry 7 (1989) 59-67
17. Klett C.J., and Caffey E. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Archives of General Psychiatry 26 4 (1972) 374-379
18. Li X.M., Perry K.W., Wong D.T., and Bymaster F.P. Psychopharmacology 136 (1998) 153-161
19. Marshall M. An overview of drugs in Oceania. In: Lindstrom L. (Ed). Drugs in Western Pacific Societies: Relations of Substances (1987), University Press of America, Lanham 13-29
20. Moltzen E.K., and Bjornholm B. Medicinal chemistry of muscarinic agonist developments since 1990. Drugs of the Future 20 (1995) 37-54
21. Olianas M.C., Maullu C., and Onali P. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 20 3 (1999) 263-270
22. Perry K.W., Nisenbaum L.K., George C.A., Shannon H.E., Felder C.C., and Bymaster F.P. The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biological Psychiatry 49 8 (2001) 716-725
23. Pfeiffer C.C., and Jenney E.H. The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Annals of the New York Academy of Sciences 66 (1957) 753-764
24. Regmi S.K., Pokharel A., Ojha S.P., Pradhan S.N., and Chapagain G. Nepal mental health country profile. International Review of Psychiatry 16 (2004) 142-149
25. Rey M.J., Schulz P., Costa C., Dick P., and Tissot R. Guidelines for the dosage of neuroleptics I: chlorpromazine equivalents of orally administered neuroleptics. International Clinical Psychopharmacology 4 2 (1989) 95-104
26. Russo J., Trujillo C.A., Wingerson D., Decker K., Ries R., Wetzler H., and Roy-Byrne P. The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients. Medical Care 36 5 (1998) 752-756
27. Shannon H.E., Rasmussen K., Bymaster F.P., Hart J.C., Peters S.C., Swedberg M.D., Jeppesen L., Sheardown M.J., Sauerberg P., and Fink-Jensen A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophrenia Research 42 3 (2000) 249-259
28. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., and Dunbar G.C. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 Supp. 20 (1998) 22-33
29. Sullivan R.J., Allen J.S., Otto C., Tiobech J., and Nero K. Effects of chewing betel nut (Areca catechu) on symptoms of people with schizophrenia in Palau, Micronesia. British Journal of Psychiatry 177 (2000) 175-178
30. Sullivan R.J., Andres S., Otto C., Miles W., and Kydd R. The effects of indigenous muscarinic drug, betel nut (Areca catechu), on the symptoms of schizophrenia: a longitudinal study in Palau, Micronesia. American Journal of Psychiatry 164 (2007) 670-673
31. Tandon R. Cholinergic aspects of schizophrenia. British Journal of Psychiatry 174 Suppl. 37 (1999) 7-11
32. Tandon R., and Greden J.F. Cholinergic hyperactivity and negative schizophrenic symptoms: a model of cholinergic/dopaminergic interactions in schizophrenia. Archives of General Psychiatry 46 (1989) 745-753
33. Tandon R., Mann N.A., Eisner W.H., and Coppard N. Effect of anticholinergics medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Research 31 3 (1990) 235-241
34. Tzavara E.T., Bymaster F.P., Davis R.J., Wade M.R., Perry K.W., Wess J., McKinzie D.L., Felder C., and Nomikos G.G. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 18 12 (2004) 1410-1412
35. Wang C.K., Lee W.H., and Peng C.H. Contents of phenolics and alkaloids in Areca catechu. Journal of Agricultural Food Chemicals 45 (1997) 1185-1188
36. Weissman M.M., Olfson M., Gameroff M.J., Feder A., and Fuentes M. A comparison of three scales for assessing social functioning in primary care. American Journal of Psychiatry 158 (2001) 460-466
37. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64 6 (2003) 663-667
38. Von Euler U.S., and Domeij B. Nicotine-like actions of arecoline. Acta Pharmacologica et Toxicologica 1 (1945) 263-269